CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 87 enrolled
Drug / intervention
escitalopram oxalatedrug
Likely dose
escitalopram oxalate 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01401595
NCT01401595Phase 3Completed
CompareCT.gov

Brain Imaging and Treatment Studies of the Night Eating Syndrome

University of Pennsylvania·interventional·Posted Jul 25, 2011·Updated Jul 15, 2020

In Brief

A Phase 3 clinical trial evaluating escitalopram oxalate for Night Eating Syndrome. Completed, enrolled 87 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNight Eating Syndrome
CountriesUnited States
CollaboratorsForest Laboratories

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 25, 2011
Enrollment StartDec 1, 2009
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.9 years ago

Interventions

escitalopram oxalatedrug

The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 31 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.